Luitpold Animal Health Becomes American Regent Animal Health January 1

The name change reflects the company's commitment to animal health while unifying the company under a common set of values, goals and operating principles.
Author:
Publish date:
American Regent Animal Health logo

Luitpold Animal Health, a division of Luitpold Pharmaceuticals, Inc., manufacturer of Adequan (polysulfated glycosaminoglycan) for horses and dogs, will become American Regent Animal Health effective Jan. 1, 2019. 

The change reflects the company's commitment to animal health while unifying the company under a common set of values, goals and operating principles. 

Luitpold Pharmaceuticals, Inc. will streamline its operations by absorbing its wholly-owned subsidiaries American Regent, Inc., and PharmaForce, Inc., into one corporate entity as of December 31, 2018. Although Luitpold will be the surviving entity, its name will be changed to “American Regent, Inc.” following the merger.

“This change allows us to draw on the strength of the American Regent brand and U.S. manufacturing footprint to continue delivering on the promise of better solutions for the health and wellbeing of animals,” said Joel Steckler, vice president, Commercial Operations, American Regent Animal Health. “Our commitment remains unwavering, as this evolution will position us to stay relevant to the needs of our customers and continue advancing a leading portfolio of animal health products that is anchored by Adequan.”

American Regent is a strong, well-recognized brand with 50 years of history that is best known for its human pharmaceutical products. The company is widely known in the United States for providing high quality, trusted products for treating iron deficiency and generic specialty injectables.

“While our company name is changing, all customer service, manufacturing, sales and distribution channels will remain the same,” added Steckler. “We will continue to provide our customers with proven products and continue to place emphasis on best-of-class service.”

Luitpold Pharmaceuticals entered the animal health market in 1984. The company released its marquis animal health product, Adequan i.m. for horses in 1989 and Adequan for dogs in 1997. The company maintains the only FDA-approved polysulfated glycosaminoglycan manufacturing site in the world. Until recently, Adequan Canine was marketed under a licensing agreement by another animal health company. In April 2018, the company brought Adequan Canine back into its portfolio, signaling its renewed commitment to animal health and additional growth in the space. Now, as American Regent Animal Health, the company will further expand its product line and seek new innovations in the animal health space to bring to market.

For customer support or to reach an American Regent Animal Health sales representative, please call 800-458-0163. For more information, visit ARAnimalHealth.com.

About American Regent Animal Health

American Regent Animal Health, formerly known as Luitpold Animal Health, is a division of American Regent, Inc. American Regent Animal Health is committed to advancing animal health with proven FDA-approved products like Adequan. The company’s portfolio is anchored by the only FDA-approved polysulfated glycosaminoglycan products for horses and dogs, which have been relied on for nearly three decades by veterinarians. American Regent, Inc., a Daiichi Sankyo Group Company, manufactures and distributes human and veterinary pharmaceutical products and is committed to providing the ever-changing U.S. healthcare marketplace with a growing and diversified portfolio under the American Regent brand. For more information on American Regent Animal Health, visit ARAnimalHealth.com or call 800-458-0163. 

AAEP-MediaPartner_1968x1100
AVMA-PLIT-logo_resized
BEVA-logo_3757x2100
WEVA-Logo-Dark-Background_1789x1000
NZEVA-logo_1100x1968

ISELP-logo_1100x1968

AAEVT-logo_2050x3667